St Jude Medical (SJM) has launched ILUMIEN Optis system, a next-generation technology designed to help physicians make personalised stenting decisions based on each patient's unique anatomy and disease state. The ILUMIEN Optis system remains the only combined fractional flow reserve (FFR) and intravascular optical coherence tomography (OCT) imaging technology platform. Together, FFR and OCT offer physicians a physiological and anatomical view of the coronary vessels to help diagnose and treat coronary artery disease. The ILUMIEN Optis system provides enhancements to the ILUMIEN system, including a first-of-its-kind stent planning software tool.
Japan becomes the first market to offer the next-generation FFR and OCT ILUMIEN Optis system for stent placement. ILUMIEN Optis comes with both English and Japanese language options.
The Pressure Wire Aeris Wireless FFR Measurement System collects detailed analyses of blood flow blockages in the coronary vessels to help determine which specific blockages are causing the patient's blood flow to be ineffective. The FFR pressure guidewire is directed through the coronary arteries and across the narrowed vessel, taking measurements as the guidewire is pulled back through the narrowed part of the artery.
The OCT technology in the new ILUMIEN Optis system uses the Dragonfly JP Imaging Catheter to capture near-infrared light imaging and measure important vessel characteristics otherwise invisible or difficult to assess with older intracoronary imaging tools. New high resolution setting and real-time, 3D reconstruction with the ILUMIEN Optis provide a 360 degree panoramic view of the vessel, which makes it easier for physicians to visualise the anatomy they are treating.
The FFR and OCT measurements captured by the ILUMIEN Optis system allow physicians to more easily differentiate plaque build-up and determine if the narrowed arteries are causing ischaemia, ultimately assisting in stent placement. 3D representation enables better visualisation in preparation for stenting and evaluation of the stent's position once placed. These advanced functionalities have previously only been available off-line.
Results from the original FAME trial found that instances of major adverse cardiovascular events were reduced in patients whose treatment was guided by FFR rather than by standard angiography alone. The FAME 2 study revealed the number of patients returning to the hospital for urgent care was 86 per cent lower for patients with stable coronary artery disease whose stenting procedure was guided by FFR than for those who received medical therapy alone.